S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
US, UK navies say they responded to distress call as Iran's Revolutionary Guard 'harassed' ship
Greek authorities rescue 91 migrants from river islet on border with Turkey
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian stocks follow Wall St up after strong US jobs report
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
US, UK navies say they responded to distress call as Iran's Revolutionary Guard 'harassed' ship
Greek authorities rescue 91 migrants from river islet on border with Turkey
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian stocks follow Wall St up after strong US jobs report
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
US, UK navies say they responded to distress call as Iran's Revolutionary Guard 'harassed' ship
Greek authorities rescue 91 migrants from river islet on border with Turkey
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian stocks follow Wall St up after strong US jobs report
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
US, UK navies say they responded to distress call as Iran's Revolutionary Guard 'harassed' ship
Greek authorities rescue 91 migrants from river islet on border with Turkey
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian stocks follow Wall St up after strong US jobs report
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024

Xenon Pharmaceuticals (XENE) Stock Forecast, Price & News

$38.96
+0.31 (+0.80%)
(As of 06/2/2023 08:49 PM ET)
Compare
Today's Range
$38.08
$39.08
50-Day Range
$34.44
$43.54
52-Week Range
$26.25
$43.57
Volume
351,500 shs
Average Volume
392,923 shs
Market Capitalization
$2.48 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.50

Xenon Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.08 Rating Score
Upside/​Downside
32.2% Upside
$51.50 Price Target
Short Interest
Healthy
4.77% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.09mentions of Xenon Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$4.47 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.79) to ($3.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

378th out of 980 stocks

Pharmaceutical Preparations Industry

182nd out of 485 stocks


XENE stock logo

About Xenon Pharmaceuticals (NASDAQ:XENE) Stock

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Receive XENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XENE Stock News Headlines

This NASDAQ Stock Is The Amazon Of Medical Supply
This Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More Now
Stifel Nicolaus Keeps Their Buy Rating on Xenon (XENE)
Stifel Nicolaus Reaffirms Their Buy Rating on Xenon (XENE)
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
Stifel Nicolaus Sticks to Their Buy Rating for Xenon (XENE)
SVB Securities Reaffirms Their Buy Rating on Xenon (XENE)
See More Headlines

XENE Price History

XENE Company Calendar

Last Earnings
5/09/2023
Today
6/05/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XENE
Employees
149
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$51.50
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$45.00
Forecasted Upside/Downside
+32.2%
Consensus Rating
Buy
Rating Score (0-4)
3.08
Research Coverage
13 Analysts

Profitability

Net Income
$-125,370,000.00
Net Margins
-862.06%
Pretax Margin
-21,950.30%

Debt

Sales & Book Value

Annual Sales
$9.43 million
Book Value
$10.81 per share

Miscellaneous

Free Float
59,710,000
Market Cap
$2.48 billion
Optionable
Optionable
Beta
1.42

Key Executives

  • Ian C. Mortimer
    President, Chief Executive Officer & Director
  • Sherry Aulin
    Chief Financial Officer
  • Sheila M. Grant
    Executive VP-Research & Development Operations
  • Christopher KenneyChristopher Kenney
    Chief Medical Officer
  • Robin Sherrington
    Executive Vice President-Strategy & Innovation













XENE Stock - Frequently Asked Questions

Should I buy or sell Xenon Pharmaceuticals stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" XENE shares.
View XENE analyst ratings
or view top-rated stocks.

What is Xenon Pharmaceuticals' stock price forecast for 2023?

13 brokerages have issued 1-year target prices for Xenon Pharmaceuticals' stock. Their XENE share price forecasts range from $45.00 to $60.00. On average, they predict the company's share price to reach $51.50 in the next year. This suggests a possible upside of 32.2% from the stock's current price.
View analysts price targets for XENE
or view top-rated stocks among Wall Street analysts.

How have XENE shares performed in 2023?

Xenon Pharmaceuticals' stock was trading at $39.43 at the beginning of 2023. Since then, XENE shares have decreased by 1.2% and is now trading at $38.96.
View the best growth stocks for 2023 here
.

When is Xenon Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our XENE earnings forecast
.

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) issued its quarterly earnings results on Tuesday, May, 9th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by $0.01. Xenon Pharmaceuticals had a negative trailing twelve-month return on equity of 20.01% and a negative net margin of 862.06%. During the same period in the previous year, the business earned ($0.35) EPS.

What other stocks do shareholders of Xenon Pharmaceuticals own?
What is Xenon Pharmaceuticals' stock symbol?

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Who are Xenon Pharmaceuticals' major shareholders?

Xenon Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (7.49%), Braidwell LP (3.36%), Pictet Asset Management SA (3.18%), Commodore Capital LP (2.90%), Perceptive Advisors LLC (2.88%) and BVF Inc. IL (2.88%). Insiders that own company stock include Christopher John Kenney, Frank A Holler, Gary Patou, Ian Mortimer, James R Empfield, Seggern Christopher Von, Sherrington Robin and Simon N Pimstone.
View institutional ownership trends
.

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xenon Pharmaceuticals' stock price today?

One share of XENE stock can currently be purchased for approximately $38.96.

How much money does Xenon Pharmaceuticals make?

Xenon Pharmaceuticals (NASDAQ:XENE) has a market capitalization of $2.48 billion and generates $9.43 million in revenue each year. The biopharmaceutical company earns $-125,370,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis.

How many employees does Xenon Pharmaceuticals have?

The company employs 149 workers across the globe.

How can I contact Xenon Pharmaceuticals?

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The official website for the company is www.xenon-pharma.com. The biopharmaceutical company can be reached via phone at (604) 484-3300, via email at investors@xenon-pharma.com, or via fax at 604-484-3450.

This page (NASDAQ:XENE) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -